YAG Laser Vitreolysis for Vitreous Floaters
Launched by VMR CONSULTING, INC. · Apr 3, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment for annoying eye floaters, which are those little spots or lines you sometimes see that can interfere with your vision. The treatment uses a special type of laser called Nd:YAG, approved by the FDA, to target the floaters in the gel-like substance (vitreous) in the eye. The goal of the study is to see how this treatment affects your vision and overall quality of life.
To participate in this trial, you must be at least 18 years old and have floaters that have been bothering you for at least three months. The study will only include one eye per patient, and certain eye conditions must be met for eligibility. Participants will attend appointments to receive the treatment and follow-ups to monitor their progress. If you're interested in joining this study, it's important to discuss your eye health with the study team to ensure you meet the criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Only one eye per patient will be included in this study
- • Able and willing to give informed consent
- • Age ≥18 years
- • Suffering from symptomatic vitreous floaters
- * Floaters arising from either/both:
- • myopic vitreopathy
- • posterior vitreous detachment
- * Floaters meeting the following characteristics:
- • Present for ≥3 months
- • One single or more dense and well-defined vitreous opacities,
- • A Weiss Ring or opacities which are within the safety area, at least 3mm away from the retina and 6mm away from the lens
- • Visible on contact lens biomicroscopy
- Exclusion Criteria:
- • Patient presenting with vitreous opacities outside of the described safety area (within 3mm of the retina or 6mm from the lens)
- • Have clinically significant cataract (lens opacification) in one or both eyes which are in the opinion of the examining doctor more significant in impacting vision as compared to that caused by vitreous opacities; or cataract expected to need cataract surgery during the duration of the study
- • Present with untreated retinal tears or retinal holes requiring treatment at the discretion of the study investigator
- • Have high risk of peripheral lesions requiring treatment at the discretion of the study investigator
- • Have synchysis scintillans (unusual vitreous opacities from old blood)
- • Have asteroid hyalosis (unusual vitreous opacities from cholesterol)
- • Have vitreous hemorrhage (fresh blood in the center of the eye)
- • Have active photopsia (flashing lights)
- • History of previous YAG laser vitreolysis treatments, or vitrectomy for any condition (retinal detachment, proliferative diabetic retinopathy, etc.)
- • Have Posterior Vitreous Detachment (separation of vitreous away from the retina lining the inside of the back of the eye) within the past 3 months
- • Are unable to attend study appointments
- • Have any other significant ocular or non-ocular condition that, at the discretion of the study investigator, puts the subject at risk or influences the results of the study
- • History of intraocular surgery within 6 months from study entry
- • History of retinal laser within 2 months from study entry
About Vmr Consulting, Inc.
VMR Consulting, Inc. is a specialized clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong focus on optimizing clinical trial design and execution, VMR Consulting partners with biotech and pharmaceutical companies to deliver high-quality, data-driven solutions. The firm leverages its extensive expertise in regulatory compliance, patient recruitment, and data management to streamline the clinical development process, ensuring timely and efficient trial outcomes. Committed to fostering collaboration and transparency, VMR Consulting is at the forefront of transforming clinical research into meaningful advancements in patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Huntington Beach, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported